Referral C-181/24 (Genmab, 6 Mar 2024)

Must Article 3(b) and (d) of Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products be interpreted as meaning that a marketing authorisation predating the marketing authorisation appearing in the application for a supplementary protection certificate and referring to the same product must be regarded as the first marketing authorisation for the purposes of that regulation, even where that prior marketing authorisation was withdrawn prior to the submission of the application for the certificate?